Targeted treatments plus engineered immune cells may slow early spread of triple‑negative breast cancer, study reveals

A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease. Published recently in Cancer Letters, Gabriel Duda, Ph.D., scientific director of transplant oncology and therapeutics at Houston Methodist Research Institute, and his research team discovered pairing targeted treatments with CAR T-cell therapy may help control cancer recurrence when intervention options are otherwise limited.